Mark A. Socinski - Publications, H-index & Citations

Mark A. Socinski

AdventHealth Cancer Institute

84H指数

782论文数

3.6W被引数

收录论文 142

发表时间

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial 在转移性鳞状非小细胞肺癌中使用clotistobart或多西他赛: 随机3期PRESERVE-003试验的1期

Nature Medicine

IF50

2026-03-27

OAAI

Byoung Chul Cho; Rama Balaraman; Hua-Jun Chen; Xinmin Yu; Adewale Fawole; Zhi-gang Liu; Jiliang Zhang; Long Wu; Bin Yang; Jennifer L. Leddon; John Hamm; Yanjing Huang; Lin Wu; Pinhua Pan; Preet Singh; Andrew Beardsley; Fadi Kayali; Ardalan Davarifar; Ki Hyeong Lee; Keon-Uk Park; Youngjoo Lee; Luchun Li; Xicheng Wang; Meili Sun; Yan Yu; Vikram Jain; Svetlana Shpyro; Qiong Wang; Michael Wenger; Uğur Şahin; Sergey Efuni; Shiling Song; Kun He; Pan Zheng; Yang Liu; Kai He; Tianhong Li; Mark A. Socinski; Yi-Long Wu

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations 非小细胞肺癌分子亚型和免疫治疗组合的脆弱性

Nature Communications

IF15.7

2025-12-03

OAAI

Tianshi Lu; Habib Hamidi; Mark A. Socinski; Martin Reck; Federico Cappuzzo; Fabrice Barlesi; Robert M. Jotte; Sören Müller; Aditi Qamra; Assaf Amitai; Xiangnan Guan; Eloisa Fuentes; Hartmut Koeppen; Jennifer M. Giltnane; David S. Shames; Marcus Ballinger; Meng Xiao He; Yulei Wang; Minu K. Srivastava; Barzin Y. Nabet

In Reply 回复

ONCOLOGIST

IF4.2

2025-09-01

PREAI

Penault-Llorca, Frederique; Socinski, Mark A.

Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials 数字与人工PD-L1评分在晚期非小细胞肺癌中的应用比较：基于IMpower110和IMpower150试验

Journal of Thoracic Oncology

IF20.8

2025-08-05

PREAI

Roy S. Herbst; Hen Prizant; Daniel Ruderman; Jake Conway; John Shamshoian; Hartmut Koeppen; Wei Zou; Filippo de Marinis; Giuseppe Giaccone; Jacek Jassem; David R. Spigel; Mark A. Socinski; Martin Reck; Luciana Molinero; Marcus Ballinger; David Shames; Michael Griffin; Limin Yu; Nishant Agrawal; Andrew Beck; Ilan Wapinski; Stephanie Hennek; Jennifer Giltnane; Minu K. Srivastava

Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)非小细胞肺癌（NSCLC）中获得性EGFR耐药突变的发生率及其分子相关性

EXPERT REVIEW OF ANTICANCER THERAPY

IF2.8

2025-04-17

PREAI

Raez, Luis E.; Baca, Yasmine; Ribeiro, Jennifer R.; Nieva, Jorge J.; Mamdani, Hirva; Lopes, Gilberto; Borghaei, Hossein; Socinski, Mark; Wozniak, Antoinette J.; Vanderwalde, Ari; Uribe, Carlos Carracedo; Sumarriva, Daniel; Khan, Hina; Liu, Stephen V.; Nagasaka, Misako

Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy

CLINICAL LUNG CANCER

IF3.3

2025-01-01

OAAI

Fortman, Dylan; Wang, Hong; Vanderweele, Robert; Evans, Terry; Herman, James G.; Rhee, John; Reyes, Vincent; Mclaughlin, Brian; Wozniak, Antoinette; Somasundaram, Ashwin; Mekhail, Tarek; Socinski, Mark A.; Schulze, Katja; Villaruz, Liza C.

Correlation of safety and efficacy of atezolizumab therapy across indications

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2024-11-12

OAAI

Duran-Pacheco, Gonzalo; Chandler, G. Scott; Maiya, Vidya; Socinski, Mark A.; Sonpavde, Guru; Puente, Javier; Essioux, Laurent; Carter, Corey; Cardona, Jose Vicente; Mohindra, Rajat; Naidoo, Jarushka

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

ESMO OPEN

IF8.3

2024-04-01

OAAI

Rodon, J.; Rodriguez, E.; Maitland, M. L.; Tsai, F. y. -c.; Socinski, M. A.; Berlin, J. D.; Thomas, J. S.; Al Baghdadi, T.; Wang, I. -m.; Guo, C.; Golmakani, M.; Clark, L. N.; Gazdoiu, M.; Li, M.; Tolcher, A. W.

A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

BMC CANCER

IF3.4

2024-03-25

OAAI

Li, Lee X.; Socinski, Mark A.; Kichenadasse, Ganessan; Karapetis, Christos S.; Shahnam, Adel; Mckinnon, Ross A.; Rowland, Andrew; Hopkins, Ashley M.; Sorich, Michael J.

A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

ECLINICALMEDICINE

IF10

2023-12-01

OAAI

Shaverdashvili, Khvaramze; Reyes, Vincent; Wang, Hong; Mehta, Dhaval; Marsh, Christopher; Waas, John K.; Vanderweele, Robert A.; Peracha, Sajid M.; Liang, Hongmei; Socinski, Mark A.; Gerber, David E.; Dowell, Jonathan E.; Villaruz, Liza C.

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked 卡铂，培美曲塞和贝伐单抗联合或不联合阿特珠单抗治疗具有敏感EGFR突变或从未吸烟的IV期非鳞状非小细胞肺癌患者的II期随机试验

CLINICAL LUNG CANCER

IF3.3

2023-11-01

PREAI

Bodor, J. Nicholas; Patel, Jyoti D.; Wakelee, Heather A.; Levy, Benjamin P.; Borghaei, Hossein; Pellini, Bruna; Costello, Michael R.; Dowell, Jonathan E.; Finley, Gene; Huang, Chao H.; Neal, Joel W.; Nieva, Jorge J.; Puri, Sonam; Socinski, Mark A.; Thomas, Christian; Ross, Eric A.; Litwin, Samuel; Clapper, Margie L.; Treat, Joseph

Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

PREAI

Le, X.; Robichaux, J. P.; Nilsson, M. B.; Ramaswamy, V.; Ravichandran, A.; Wu, J.; Elamin, Y. Y.; Hong, L.; Udagawa, H.; Socinski, M.; Bhat, G.; Lebel, F.; Vincent, S.; Bunn, V.; Su, Z.; Lawson, J.; Cross, J.; Heymach, J.

Correlation of safety and efficacy in atezolizumab therapy across indications

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

PREAI

Naidoo, J.; Duran-Pacheco, G.; Maiya, V.; Socinski, M.; Sonpavde, G. P.; Puente, J.; Essioux, L.; Carter, C. A.; Cardona, J. V.; Mohindra, R.; Chandler, S. G.

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer

FRONTIERS IN ONCOLOGY

IF3.3

2023-08-28

OAAI

Hsu, Robert; Chen, Denaly; Xia, Bing; Feldman, Rebecca; Cozen, Wendy; Raez, Luis E.; Borghaei, Hossein; Kim, Chul; Nagasaka, Misako; Mamdani, Hirva; Vanderwalde, Ari M.; Lopes, Gilberto; Socinski, Mark A.; Wozniak, Antoinette J.; Spira, Alexander I.; Liu, Stephen V.; Nieva, Jorge J.

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer 基于循环肿瘤DNA的纵向模型与转移性非小细胞肺癌的生存相关

NATURE MEDICINE

IF50

2023-03-16

OAAI

Assaf, Zoe June F.; Zou, Wei; Fine, Alexander D.; Socinski, Mark A.; Young, Amanda; Lipson, Doron; Freidin, Jonathan F.; Kennedy, Mark; Polisecki, Eliana; Nishio, Makoto; Fabrizio, David; Oxnard, Geoffrey R.; Cummings, Craig; Rode, Anja; Reck, Martin; Patil, Namrata S.; Lee, Mark; Shames, David S.; Schulze, Katja

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

FRONTIERS IN ONCOLOGY

IF3.3

2023-02-01

OAAI

Villaruz, Liza C.; Socinski, Mark A.; Weiss, Jared

A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors 新型冠状病毒肺炎感染对接受免疫检查点抑制剂的癌症患者免疫相关不良事件影响的单中心回顾性研究

JOURNAL OF IMMUNOTHERAPY

IF2.9

2022-09-05

OAAI

Guo, Mengni; Liu, Jieying; Miao, Ruoyu; Ahmed, Zohaib; Yu, James; Guan, Jian; Ahmad, Sarfraz; Zhou, Shuntai; Grove, Angela; Manoucheri, Manoucher; Socinski, Mark A.; Mekhail, Tarek

The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework

FRONTIERS IN ONCOLOGY

IF3.3

2022-06-10

OAAI

Liu, Stephen, V; Nagasaka, Misako; Stefaniak, Victoria; Gruver, Kristi; Lin, Yong; Ferry, David; Socinski, Mark A.; Zhang, Li

A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer PF-06747775单药或联合帕博西尼治疗表皮生长因子受体突变型晚期非小细胞肺癌的1b/2期研究

EXPERT OPINION ON INVESTIGATIONAL DRUGS

IF4.1

2022-06-03

OAAI

Cho, Byoung Chul; Goldberg, Sarah B.; Kim, Dong-Wan; Socinski, Mark A.; Burns, Timothy F.; Lwin, Zarnie; Pathan, Nuzhat; Ma, Wei Dong; Masters, Joanna C.; Cossons, Nandini; Wilner, Keith; Nishio, Makoto; Husain, Hatim

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

NATURE MEDICINE

IF50

2022-04-14

OAAI

Kim, Edward S.; Velcheti, Vamsidhar; Mekhail, Tarek; Yun, Cindy; Shagan, Sarah M.; Hu, Sylvia; Chaes, Young Kwang; Leal, Ticiana A.; Dowell, Jonathan E.; Tsai, Michaela L.; Dakhil, Christopher S. R.; Stella, Philip; Jin, Yanling; Shames, David S.; Schleifman, Erica; Fabrizio, David A.; Phan, See; Socinski, Mark A.

研究方向